Chaeum Premium No. 4: Regulatory Status and Market Access for Professionals

Chaeum Premium No. 4 is a hyaluronic acid (HA) dermal filler developed by Hugel, a prominent South Korean pharmaceutical company. The product is designed for professional use in aesthetic procedures. Hugel maintains a portfolio of aesthetic solutions, with Chaeum Premium No. 4 forming part of its offering to the international market.

As a hyaluronic acid dermal filler, its composition and manufacturing process are subject to specific regulatory oversight in its country of origin and target export markets. Professionals considering this product for their clinic's inventory should prioritize a clear understanding of its documented compliance.

The regulatory journey for aesthetic injectables involves adherence to national and international standards. For products originating from South Korea, the Korea Ministry of Food and Drug Safety (KFDA) approval is primary. Hugel products, including the Chaeum line, are produced under KFDA guidelines.

• KFDA Approval: As a South Korean manufactured product, Chaeum Premium No. 4 holds KFDA approval for distribution within South Korea.
• CE Mark (EU Compliance): The CE Mark is crucial for legal distribution within the European Union. While Hugel has secured CE Marks for various products, the specific CE status for Chaeum Premium No. 4 should be confirmed directly with official distributors or the manufacturer. [VERIFY: Chaeum Premium No. 4 CE Mark status]
• FDA Approval (United States): Obtaining U.S. Food and Drug Administration (FDA) approval is a distinct and rigorous process. [VERIFY: Chaeum Premium No. 4 FDA approval status]
• GMP and ISO Standards: Hugel's manufacturing facilities are generally recognized for adhering to Good Manufacturing Practices (GMP) and ISO quality management standards, which are fundamental for product quality and safety worldwide.

The ability to legally import and distribute Chaeum Premium No. 4 varies significantly by region. Clinics must ensure their sourcing aligns with local regulations to avoid legal and professional liabilities.

• European Union & UK: Access often hinges on a valid CE Mark or specific national marketing authorizations. Without these, importation may be restricted or illegal. Professionals should consult local regulatory bodies or authorized European distributors.
• GCC (Gulf Cooperation Council): Countries like Saudi Arabia, UAE, and Qatar typically require local Ministry of Health (MOH) or equivalent authority registration for aesthetic products. [VERIFY: Chaeum Premium No. 4 specific GCC market authorizations]
• LATAM (Latin America): Each country in Latin America (e.g., Brazil, Mexico) has its own regulatory agency (e.g., ANVISA, COFEPRIS) and approval process for medical devices and injectables. Professionals should verify local registration prior to procurement.
• APAC (Asia-Pacific): Beyond KFDA, other APAC countries like Australia (TGA), Singapore (HSA), or Malaysia (MDA) have distinct requirements. Market presence in these regions would depend on specific national registrations.

Parallel imports refer to genuine products purchased in one market and imported into another without the authorization of the manufacturer's official distributor. While sometimes offering a lower price point, this practice carries significant risks for professional buyers.

Key risks include: lack of official warranties, uncertain cold chain management, potential for products not intended for the target market's specific regulations, and challenges in verifying authenticity or lot-specific details. Sourcing through official channels is critical for clinic integrity and patient safety. For guidance on verifying product authenticity, consider resources such as our guide on Verifying Genuine Elravie Premier UD: An Anti-Counterfeit Gu.

When exploring options for your clinic's hyaluronic acid dermal filler catalog, ensuring verifiable product provenance is paramount.

When procuring Chaeum Premium No. 4, professionals must demand comprehensive documentation from their suppliers. This helps verify the product's legitimacy, quality, and proper handling.

Required documentation typically includes:

• Certificate of Analysis (CoA): Lot-specific testing results confirming product specifications.
• Certificate of Origin: Verifies the product's country of manufacture (South Korea).
• Certificate of Authenticity/Manufacturer Statement: Proof that the product is genuine and supplied through an authorized channel.
• Cold Chain Documentation: Evidence that temperature-sensitive products were stored and transported correctly.
• Batch/Lot Numbers: Essential for traceability and recall procedures.

Without these documents, the provenance and quality assurance of the product cannot be definitively established, posing potential risks for clinics.

For professionals planning their procurement strategy, understanding potential pricing structures is essential. As an illustrative example, Chaeum Premium No. 4 may be offered at a wholesale price point of approximately $106.8 per unit. Suppliers often provide tiered volume discounts to encourage larger orders.

An example of such a tier structure could be:

• 11+ units: 4% discount
• 21+ units: 5% discount
• 31+ units: 6% discount
• 51+ units: 8% discount

These figures are illustrative and subject to market fluctuations, supplier agreements, and regional pricing strategies. For specific quotes and updated pricing, direct inquiry with wholesale distributors is recommended. This allows for comparing options with other professional-grade fillers, such as those discussed in Metoo Fill+: A Professional Comparison for Sourcing Dermal F or Dermalax Deep / Plus: A Professional Comparison for Sourcing.